PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25225F0191Delivery ORDER for a BASE PLUS — Novartis Pharmaceuticals Corp

Novartis Pharmaceuticals Corp holds $23.5M across 59 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79720D0180. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Aug 31, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

252-Network Contract Office 12 (36C252)

Awarding office

Novartis Pharmaceuticals Corp

Recipient

Aug 31, 2026

PoP end

$1M

Obligated

$2.2M

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Novartis Pharmaceuticals Corp — $90

Contract facts

Federal

Contract number36C25225F0191

Also listed as36C252-25-F-0191

Also listed as36F79720D0180-36C25225F0191

Agency252-Network Contract Office 12 (36C252)

Awarding office252-Network Contract Office 12 (36C252)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentNovartis Pharmaceuticals Corp

CAGE04520

UEING61ZA8TADW3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0180

Place of performanceEAST HANOVER NJ

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 1, 2025

PoP end (current)Aug 31, 2026

PoP end (w/ options)Aug 31, 2027

Obligated$1M

Current value$1M

Potential value$2.2M

DELIVERY ORDER FOR A BASE PLUS ONE (1) OPTION YEAR FOR THE RADIOPHARMACEUTICAL PLUVICTO. is a federal award for 252-Network Contract Office 12 (36C252) held by Novartis Pharmaceuticals Corp. Estimated value $2.2M ($1M obligated). Current period of performance ends Aug 31, 2026 (potential Aug 31, 2027). Last award drew 1 bidder. Place of performance: EAST HANOVER NJ.

DELIVERY ORDER FOR A BASE PLUS ONE (1) OPTION YEAR FOR THE RADIOPHARMACEUTICAL PLUVICTO.

Recompete timing

Public

● Past PoP end (10 days ago)

Current PoP ended Aug 31, 2026 (10 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Novartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($23.5M) · all agencies

Department of Veterans Affairs (VA)$37.6M · 160%Department of Defense (DOD)$4.7M · 20%

Open full company profile →

Related awards

Same parent · incumbent

36C24125F0148

PLUVICTO

$810K

Sep 14, 2026

36C26126F0007

PLUVICTO DRUG

$4.0M

Sep 30, 2026

W81K0025FA195

LUTATHERA AND PLUVICTO

$3.2M

Sep 30, 2026

36C26126F0017

PLUVICTO FY26

$1.6M

Sep 30, 2026

36C25026N0006

PLUVICTO

$1.2M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25225F0191?

36C25225F0191 (Delivery ORDER for a BASE PLUS) is a 252-Network Contract Office 12 (36C252) award with a potential value of $2.2M, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C252-25-F-0191?

36C252-25-F-0191 is the dashed form of PIID 36C25225F0191 (Delivery ORDER for a BASE PLUS), held by Novartis Pharmaceuticals Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25225F0191?

252-Network Contract Office 12 (36C252) awarded 36C25225F0191 to Novartis Pharmaceuticals Corp (potential $2.2M).

Who is the incumbent on 36C25225F0191?

Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2026.

When does Novartis Pharmaceuticals Corp’s 36C25225F0191 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 36C25225F0191 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthlyLatest procurement action Jan 28, 2026